GLAXO (GLAXO) Fair Value & Analysis
Healthcare · Market cap ₹409B
Fair value as of: Jul 3, 2026
From 25 valuation models · updated today
Share price +10.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹2,103 – ₹3,227 · fair‑value band ₹787.42 – ₹1,433 · the ₹2,416 price screens above the ₹1,159 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
GLAXO (GLAXO) currently trades at ₹2,416, while our model-based Fair Value estimate is ₹1,159 — implying the stock looks roughly 52.0% overvalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, GLAXO generated revenue of ₹38.2B at a net margin of 27.1%. Revenue grew 2.1% year over year. It earns a return on equity of 49.1%. The balance sheet holds a net cash position of ₹10.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
GLAXO reported revenue of ₹38.2B in FY2026 versus ₹32.6B in FY2022, a compound +4.0%/yr. Reported net income was ₹10.4B in FY2026, compounding −11.6%/yr from FY2022.
Is GLAXO fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| JNJ JNJ | 4,128 MXN | 2,944 MXN | -29% |
| Johnson & Johnson, JNJB34 | R$82.15 | R$58.27 | -29% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRK | $119.09 | $77.57 | -35% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GLAXO (GLAXO) undervalued?
What is the fair value of GLAXO?
What is the quality score of GLAXO?
What is the revenue of GLAXO (GLAXO)?
What is the net profit margin of GLAXO?
Does GLAXO pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.